pharmaphorum3 年
NICE gives Keytruda parity with Opdivo for adjuvant melanoma
Since then, MSD has also claimed approval in the US for Keytruda as adjuvant treatment of adults and children aged over 12 with stage 2b or 2c melanoma based on the KEYNOTE-716 trial, which showed ...
pharmaphorum1 个月
NICE gives Keytruda parity with Opdivo for adjuvant melanoma
Since then, MSD has also claimed approval in the US for Keytruda as adjuvant treatment of adults and children aged over 12 with stage 2b or 2c melanoma based on the KEYNOTE-716 trial, which showed ...